A Phase Ib/II Study of Cancer Sternness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.

被引：5
|
作者：
Becerra, Carlos
Braiteh, Fadi S.
Spira, Alexander I.
Langleben, Adrian
Panasci, Lawrence C.
Vukelja, Svetislava J.
Hinshaw, Ioana M.
Goodwin, Rachel Anne
Panella, Timothy J.
Edenfield, William Jeffery
Kossler, Kimiko
Hume, Stephanie
Li, Youzhi
Hitron, Matthew
Li, Chiang
机构：
[1] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[2] McKesson Specialty Hlth, US Oncol Network, The Woodlands, TX USA
[3] Virginia Canc Specialists Res Inst & Oncol Res, Fairfax, VA USA
[4] St Marys Hosp, Westmount, PQ, Canada
[5] Jewish Gen Hosp, Dept Oncol, Montreal, PQ, Canada
[6] Tyler Canc Ctr, US Oncol Res & Texas Oncol, Tyler, TX USA
[7] Rocky Mt Canc Ctr, Denver, CO USA
[8] Ottawa Hosp, Natl Canc Inst, Canada Clin Trials Grp, Ottawa, ON, Canada
[9] Univ Tennessee, Knoxville, TN USA
[10] Greenville Hosp Syst, Univ Med Ctr, Inst Translat Oncol Res, Greenville, SC USA
[11] Boston Biomed Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.1094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1094
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.
    Garcia, Agustin A.
    Hays, John L.
    Cote, Gregory Michael
    Becerra, Carlos
    Langleben, Adrian
    Lau, Susie K.
    Roman, Lynda D.
    McCormick, Colleen Catherine
    Richards, Donald A.
    Braiteh, Fadi S.
    Yimer, Habte Aragaw
    Richey, Stephen Lane
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.
    Becerra, Carlos
    Spira, Alexander I.
    Conkling, Paul R.
    Richey, Stephen Lane
    Hanna, Wahid Tewfik
    Cote, Gregory Michael
    Heist, Rebecca Suk
    Langleben, Adrian
    Laurie, Scott Andrew
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] A phase Ib extension study of cancer sternness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer.
    El-Rayes, Bassel F.
    Shanda, Safi
    Starodub, Alexander
    O'Neil, Bert H.
    Hanna, Wahid Tewfik
    Shaib, Walid Labib
    Oh, Cindy
    Li, Wei
    Li, Youzhi
    Borodyansky, Laura
    Li, Chiang
    Bekaii-Saab, Tanios S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer.
    Bekaii-Saab, Tanios S.
    Mikhail, Sameh
    Langleben, Adrian
    Becerra, Carlos
    Jonker, Derek J.
    Asmis, Timothy R.
    Cote, Gregory Michael
    Wu, Christina Sing-Ying
    Kwak, Eunice Lee
    Spira, Alexander I.
    Braiteh, Fadi S.
    Richey, Stephen Lane
    Hume, Stephanie
    Hitron, Matthew
    Li, Chiang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [5] A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.
    Edenfield, William Jeffery
    Becerra, Carlos
    Langleben, Adrian
    Spira, Alexander I.
    Braiteh, Fadi S.
    Kossler, Kimiko
    Gao, Yuan
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).
    Bekaii-Saab, Tanios S.
    Starodub, Alexander
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Shanda, Safi
    Ciombor, Kristen Keon
    Noonan, Anne M.
    Hanna, Wahid Tewfik
    Sehdev, Amikar
    Shaib, Walid Labib
    Mikhail, Sameh
    Neki, Anterpreet S.
    Oh, Cindy
    Li, Youzhi
    Li, Wei
    Borodyansky, Laura
    Li, Chiang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI plus /-bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
    O'Neil, Bert H.
    Hubbard, Joleen Marie
    Starodub, Alexander
    Jonker, Derek J.
    Edenfield, William Jeffery
    El-Rayes, Bassel F.
    Halfdanarson, Thorvardur Ragnar
    Ramanathan, Ramesh K.
    Pitot, Henry C.
    Britten, Carolyn D.
    Adesunloye, Bamidele
    Grothey, Axel
    Borodyansky, Laura
    Li, Chiang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Phase II Study of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer in Japan
    Horiguchi, Jun
    Rai, Yoshiaki
    Tamura, Kazuo
    Taki, Toshihiko
    Hisamatsu, Kazufumi
    Ito, Yoshinori
    Seriu, Taku
    Tajima, Tomoo
    [J]. ANTICANCER RESEARCH, 2009, 29 (02) : 625 - 630
  • [9] Weekly cisplatin-epirubicin-paclitaxel in advanced breast cancer. A phase I study
    Frasci, G
    Comella, P
    Apicella, A
    D'Aiuto, G
    Thomas, R
    Capasso, I
    Di Bonito, M
    Piccolo, S
    Carteni, G
    Gravina, A
    Comella, G
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
  • [10] Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer.
    Nelson, Blessie Elizabeth
    Saleem, Sadia
    Damodaran, Senthil
    Somaiah, Neeta
    Piha-Paul, Sarina Anne
    Moore, Julia Ann
    Yilmaz, Bulent
    Karp, Daniel D.
    Dumbrava, Ecaterina Elena
    Tsimberidou, Apostolia Maria
    Hong, David S.
    Ahnert, Jordi Rodon
    Booser, Daniel J.
    Ibrahim, Nuhad K.
    Conley, Anthony Paul
    Bhosale, Priya
    Hernandez, Cristhiam Mauricio Rojas
    Tripathy, Debu
    Naing, Aung
    Meric-Bernstam, Funda
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345